Working… Menu

Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01386398
Recruitment Status : Withdrawn (Company withdrew interest)
First Posted : July 1, 2011
Last Update Posted : January 21, 2015
Information provided by:
European Organisation for Research and Treatment of Cancer - EORTC

No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
Recruitment Status : Withdrawn
Primary Completion Date : No date given
Study Completion Date : No date given